Every 424B that REGENXBIO Inc. (RGNX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow RGNX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RGNX filings page.
REGENXBIO Inc. is raising capital through a primary offering of equity and pre-funded warrants under its Form S-3 shelf. The company is offering 10,003,889 shares of common stock and 1,111,111 pre-funded warrants to purchase common stock at a public offering price of $9.00 per share and $8.9999 per warrant, for an aggregate public offering price of $100,034,889. Underwriters have a 30-day option to buy up to 1,667,250 additional shares.
After $6,002,100 in underwriting discounts and estimated expenses, net proceeds are expected to be about $93.7 million, or $107.8 million if the option is fully exercised. As of March 31, 2026, net tangible book value was $0.41 per share; giving effect to the offering (excluding warrant exercise), this would increase to $1.86 per share, implying dilution of $7.14 per share to new investors. Pre-funded warrants have a $0.0001 exercise price, no expiration, and include 4.99%/9.99% beneficial ownership limits and cashless exercise features.
The company reports preliminary cash, cash equivalents and marketable securities of approximately $105.5 million at June 30, 2026, down from $150.5 million at March 31, 2026, and expects a $100.0 million milestone payment from AbbVie in July 2026. Based on its current plan and excluding this offering, it believes these resources and the AbbVie milestone are sufficient to fund operations into the second quarter of 2027, but its financial statements include a going concern explanatory paragraph. Proceeds are intended for general corporate purposes including clinical trials, pipeline development and potential commercialization of gene therapy candidates such as RGX-202 for Duchenne muscular dystrophy, for which a BLA filing via the accelerated approval pathway is anticipated in the third quarter of 2026.
REGENXBIO Inc. plans a primary offering of $100,000,000 of common stock under its shelf registration, with a 30‑day option for underwriters to purchase additional shares. Net proceeds are intended for general corporate purposes, including clinical trials, pipeline development, working capital, and potential debt repayment or acquisitions.
REGENXBIO is a clinical‑stage gene therapy company. Lead candidate RGX‑202 for Duchenne muscular dystrophy has a fully enrolled pivotal Phase III cohort (n=30) with positive topline data, and a biologics license application is targeted for the third quarter of 2026 using the FDA’s accelerated approval pathway.
The company expects cash, cash equivalents and marketable securities of approximately $105.5 million as of June 30, 2026, versus $150.5 million on March 31, 2026, and anticipates a $100.0 million AbbVie milestone in July 2026. It believes these resources will fund operations into the second quarter of 2027, while recent financial statements and risk disclosures state substantial doubt about the ability to continue as a going concern.
REGENXBIO Inc. is registering up to $150 million of common stock for an at-the-market offering through Leerink Partners, which will act as sales agent for a fee of up to 3.0% of gross proceeds. Shares may be sold from time to time on Nasdaq under the symbol RGNX or in other permitted transactions.
The company estimates it held about $241 million of cash, cash equivalents and marketable securities as of December 31, 2025 and currently expects this to fund operations into early 2027. Despite this, REGENXBIO states that there is substantial doubt about its ability to continue as a going concern within 12 months of filing its 2025 Form 10‑K and anticipates an auditor opinion including a going‑concern explanatory paragraph.
Regulatory setbacks add to the risk profile. The FDA issued a Complete Response Letter for RGX‑121, outlining several scientific concerns, and placed clinical holds on RGX‑111 and RGX‑121 after a neoplasm was observed in one RGX‑111 trial participant. The company warns these issues, along with potential dilution—illustrated by a scenario where 17,647,058 shares are sold at $8.50 per share—could materially affect its business and stock price.